Advances in immunotherapy for human epidermal growth factor receptor 2-positive breast cancer
10.3760/cma.j.cn112309-20211109-00372
- VernacularTitle:人表皮生长因子受体2阳性乳腺癌的免疫治疗进展
- Author:
Yadi ZHANG
1
;
Zheng ZHANG
;
Jiakang SHAO
;
Weihong ZHAO
Author Information
1. 中国人民解放军总医院第一医学中心肿瘤内科，北京 100853
- Keywords:
HER2-positive breast cancer;
Immunotherapy;
Targeted therapy;
Immune checkpoint inhibitors;
Cancer vaccines
- From:
Chinese Journal of Microbiology and Immunology
2022;42(8):642-646
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor 2 (HER2)-targeted therapy has greatly improved the prognosis of HER2-positive breast cancer. HER2-targeted therapy combined with chemotherapy dominated by trastuzumab+ pertuzumab is important in the neoadjuvant therapy, postoperative adjuvant therapy and late-stage standard treatment for HER2-positive breast cancer. Antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) have further improved the efficacy of therapy. However, advanced breast cancer will eventually get a recurrence or drug resistance. HER2-positive breast cancer is characterized by moderate immunogenicity with the presence of large tumor-infiltrating lymphocytes (TILs), which provides a theoretical basis for immunotherapy. The application of HER2-targeted cancer vaccines and immune checkpoint inhibitors is promising and would offer more treatment options for the patients.
